Vista Pharmaceuticals Limited Stock

Equities

VISTAPH6

INE427C01021

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:50 2024-05-15 am EDT 5-day change 1st Jan Change
13.99 INR -2.17% Intraday chart for Vista Pharmaceuticals Limited -1.82% -4.64%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2022 3.94M 47.3K Sales 2023 10.04M 120K Capitalization 312M 3.74M
Net income 2022 -8M -95.93K Net income 2023 -56M -671K EV / Sales 2022 118 x
Net Debt 2022 125M 1.5M Net Debt 2023 97.55M 1.17M EV / Sales 2023 40.8 x
P/E ratio 2022
-40.8 x
P/E ratio 2023
-5.44 x
Employees 30
Yield 2022 *
-
Yield 2023
-
Free-Float 26.74%
More Fundamentals * Assessed data
Dynamic Chart
Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Vista Pharmaceuticals Limited announced that it expects to receive INR 0.533334 million in funding CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Vista Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Vista Pharmaceuticals Limited Announces the Resignation of Mr. Nishant Talreja from the Post of Company Secretary, Compliance Officer and Key Managerial Personnel CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Vista Pharmaceuticals Limited Announces Change in Corporate Office Address CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Vista Pharmaceuticals Limited announced that it has received INR 61.895 million in funding CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Vista Pharmaceuticals Appoints Chairman MT
Vista Pharmaceuticals Limited Announces Executive Changes CI
Vista Pharmaceuticals Limited Approves Resignation of Narendra Gilaka as Independent Director of the Company CI
Vista Pharmaceuticals Limited announced that it expects to receive INR 66.895 million in funding CI
Vista Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
More news
1 day-2.17%
1 week-1.82%
Current month-0.07%
1 month+7.37%
3 months-5.47%
6 months-24.99%
Current year-4.64%
More quotes
1 week
13.32
Extreme 13.32
14.85
1 month
12.72
Extreme 12.72
15.15
Current year
10.43
Extreme 10.43
17.55
1 year
7.95
Extreme 7.95
19.70
3 years
6.51
Extreme 6.51
19.70
5 years
4.51
Extreme 4.51
19.70
10 years
2.65
Extreme 2.652
56.15
More quotes
Managers TitleAgeSince
Chief Executive Officer - 22-10-13
Founder 73 91-01-24
Director of Finance/CFO - -
Members of the board TitleAgeSince
Director/Board Member 74 94-02-16
Chief Executive Officer - 22-10-13
Director/Board Member 67 17-11-19
More insiders
Date Price Change Volume
24-05-15 13.99 -2.17% 7,707
24-05-14 14.3 -1.38% 8,119
24-05-13 14.5 +2.47% 16,015
24-05-10 14.15 +0.93% 14,313
24-05-09 14.02 -1.61% 7,600

Delayed Quote Bombay S.E., May 15, 2024 at 06:00 am EDT

More quotes
Vista Pharmaceuticals Limited is an India-based company that is engaged in manufacturing and selling of pharmaceutical, medical, and veterinary preparations. The Company also sells the products to its related companies, which are engaged in the manufacture of formulations. It offers over the counter and prescription generic drug products, consisting of tablets, capsules and liquids covering various therapeutic categories. Its products include tablet dosage forms in the United States market, such as Sulfamethoxazole & Trimethoprim, Acetaminophen, Bismuth Subsalicylate, Bismuth Subgallate, Ferrous Gluconate, Ferrous Sulfate, Pyrantel Pamoate and Isoxsuprine HCl and tablet dosage forms in the non-United States market, such as Aspirin, Atenolol, Mebendazole, Nefidipine, Quinine Sulfate, Ranitidine HCl, Magnesium Trisilicate Compound, Aluminium Hydroxide, Folic Acid and Captopril. Its capsule dosage forms in the non-United States market include Indomethacin, Piroxicam and Nefidipine.
More about the company
  1. Stock Market
  2. Equities
  3. VISTAPH6 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW